| Pharmaceutical Information |
| Drug Name |
Idarubicin hydrochloride |
| Drug ID |
BADD_D01128 |
| Description |
An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. |
| Indications and Usage |
For the treatment of acute myeloid leukemia (AML) in adults. This includes French-American-British (FAB) classifications M1 through M7. |
| Marketing Status |
approved |
| ATC Code |
L01DB06 |
| DrugBank ID |
DB01177
|
| KEGG ID |
D01747
|
| MeSH ID |
D015255
|
| PubChem ID |
636362
|
| TTD Drug ID |
D01XDL
|
| NDC Product Code |
77391-003; 58623-0027; 0143-9308; 0013-2576; 0013-2596; 0703-4156; 17337-0098; 0143-9218; 0703-4155; 0143-9219; 0143-9306; 0143-9307; 0143-9217; 0013-2586 |
| UNII |
5VV3MDU5IE
|
| Synonyms |
Idarubicin | 4-Desmethoxydaunorubicin | 4 Desmethoxydaunorubicin | 4-Demethoxydaunorubicin | 4 Demethoxydaunorubicin | IMI-30 | IMI 30 | IMI30 | NSC-256439 | NSC 256439 | NSC256439 | Idarubicin Hydrochloride | Hydrochloride, Idarubicin |
|
| Chemical Information |
| Molecular Formula |
C26H28ClNO9 |
| CAS Registry Number |
57852-57-0 |
| SMILES |
CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=CC=CC=C5C4=O)O)(C(=O)C)O)N)O.Cl |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
